Last checked at 
LONDON (Alliance News) - GlaxoSmithKline PLC said Monday results from its long-term safety study of Advair Diskus for the treatment of adults and adolescents with asthma were published in the New England Journal of Medicine.
The study, which reported results in October, compared Advair Diskus to a monotherapy of fluticasone propionate. The results were simultaneously presented at the American Academy of Asthma, Allergy and Immunology Congress in Los Angeles, California.
"We are pleased that this study, which demonstrates the safety profile of Advair, has now been presented in a well-respected, peer-reviewed journal and also presented at scientific congress. This will give physicians the opportunity to independently review the results of this study," said Chief Medical Officer Kate Knobil in a statement.
The company is also conducting a second long-term safety study in children with asthma between four and eleven years of age. This study is set to report results at the end of the first quarter of 2016.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
